| 发明名称 | Anti-cancer drug | ||
| 摘要 | The present invention is directed to an anti-cancer drug containing an anti-MFG-E8 antibody as an active ingredient, and to an anti-cancer drug which employs an anti-MFG-E8 antibody in combination with a cancer therapy employing an anti-cancer agent other than the anti-MFG-E8 antibody. | ||
| 申请公布号 | US9226934(B2) | 申请公布日期 | 2016.01.05 |
| 申请号 | US200912995942 | 申请日期 | 2009.04.28 |
| 申请人 | THE UNIVERSITY OF TOKYO | 发明人 | Tahara Hideaki;Jinushi Masahisa |
| 分类号 | A61K39/395;C07K16/00;A61K31/7068;A61K31/337;A61K31/4164;A61K31/4745;A61K31/704;A61K31/7048;A61K33/24;A61K45/06;C07K16/18;C07K16/30;A61K39/00 | 主分类号 | A61K39/395 |
| 代理机构 | Oblon, McClelland, Maier & Neustadt, L.L.P. | 代理人 | Oblon, McClelland, Maier & Neustadt, L.L.P. |
| 主权项 | 1. A method for treatment of cancer, comprising administering, to a patient in need thereof, an anti-MFG-E8 antibody and an anti-cancer agent other than the antibody, in combination, wherein said treatment is in the absence of administration of a tumor antigen or tumor cell, the anti-cancer agent is a tumor-cell-toxic anti-cancer agent, and the anti-MFG-E8 antibody and the tumor-cell-toxic anticancer agent are administered separately, and the anti-MFG-E8 antibody induces an immune response by binding to MFG-E8 to thereby inhibit the function of MFG-E8. | ||
| 地址 | Tokyo JP | ||